Liftstream is an executive search recruitment company in the life sciences sector
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
Posted in Orphan Drugs and Rare Diseases
Tagged AbbVie, Actelion, Alexion, bioValley, Boston, Boston Biotech, Flemming Ornskov, M&A, NPS Pharmaceuticals, Orphan Drug, Pfizer, Rare Disease, Shire, SOBI, Swiss, Synageva
Leave a comment